Therapeutic effect of mitomycin C in the immediate postoperative period in patients with intermediate risk non-muscle-invasive bladder tumors;Efecto terapéutico de Mitomicina C en el postoperatorio inmediato de pacientes con tumores vesicales no músculo invasores de riesgo intermedio

Actas Urologicas Espanolas

Volumn 32, Issue 9, 2008, Pages 894-903

  Jalon Monzon A ^a   Fernandez Gomez J M ^a   Escaf Barmadah, S ^b   Alvarez Mugica M ^a   Martin Benito J L ^a   Regadera Sejas, F J ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Hospital de Jave   (Spain)

Author keywords

Bladder cancer; Chemotherapy; Intravesical therapy; Mitomycin C; Non muscle invasive

Indexed keywords

EID: 56849125713     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-4806(08)73957-3     Document Type: Article

References (21)

1. Angulo JC, Sánchez M, Domínguez P, López JI, Flores N, Pontes EJ et al. La predicción de pronóstico en pacientes con carcinoma de células transicionales de la vejiga urinaria. Arch Esp Urol 1996;49 (4):374-384.
2. Miller RN. The emotional problems of patients with bladder cancer. Cancer Res 1977; 37: 2789-2791.
3. Brausi MA. New insights in the management of non-muscle-invasive bladder cancer. Eur Urol 2007; 6 (14): 787-788.
4. Oosterlinck W, van der Meijden A, Sylvester R, Böhle A, Rintala E, Solsona E et al. Guidelines on TaT1 (Non-muscle invasive). European Association of Urology Guidelines 2007: 1-17.
5. Krogh J, Kvist E, Rye B. Transitional cell carcinoma of the upper urinary tract: Prognostic variables and post-operative recurrences. Br J Urol 1991; 67: 32-36.
6. Soloway MS, Martino CC. Prophylaxis of bladder tumor implantation: Intravesical and systematic chemotherapy. Urology. 1976; 7:29-34.
7. Lamm DL. Long term results of intravesical therapy for superficial bladder cancer (Review). Urol Clin North Am. 1992;19: 573-580.
8. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130:1083-1086.
9. Sylvester RJ, Van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-477.
10. Lum BL, Toti FM. Adjuvant intravesical pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst. 1991;83:682-694.
11. Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol. 2003;169(3):921-924.
12. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published-results of randomised clinical trials. J Urol. 2004;171:2186-2190.
13. Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996 Apr;155(4): 233-1238.
14. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of two European Organization for Research and Treatment of Cancer Genitourinary Group randomizad trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol. 1995 Mar;153(3 Pt 2):934-941.
15. Millán-Rodríguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000;164:680-684.
16. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90-95.
17. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, Van Der Meijden AP, Parmar MKB et al. A combined analysis of European Organisation for Research and Treatment of Cancer, and Medical Research Council randomised clinical trials for the prophylactic treatment of stage Ta T1 bladder cancer. J Urol. 1996;156:1934-1941.
18. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin. A prospective, randomized clinical trial. J Urol. 2006;175(5): 1641-1644.
19. Solsona E, Iborra I, Ricós JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. J Urol. 1999;161:1120-1123.
20. Kaasinen E, Rintala E, Hellstrom P, Viitanen J, Juusela H, Rajala P et al. FinnBladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol. 2002;42:167-174.
21. Mostafid AH, Rajkumar RGN, Stewart AB, Singh R. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. BJU International 2006; 97:509-512.